Gilead Sciences, Inc. (GILD) Company Profile & Statistics

Gilead Sciences, Inc.
GILD
(Nasdaq - US)
N/A
67.08
+0.05 (+0.07%)
in:usd•As of: Apr 24, 2024 15:59 UTC -4
Pre Market:67.38+0.30 (+0.45%)
Open
66.55
High
67.18
Low
66.40

About Gilead Sciences, Inc.

CEO

Daniel P. O¿Day

Headquarters

333 lakeside drive

foster city, ca 94404, united states

Auditor

Ernst & Young LLP

Employees

18,000

Share Holders

1,396

Website

www.gilead.com

Industry

biotechnology

Sector

health technology

Company Overview

Gilead Sciences is a pioneer in developing drugs for the treatment of human immunodeficiency virus, liver diseases, hematology/oncology diseases and inflammation/respiratory diseases. The company has a strong HIV franchise with key HIV/AIDS therapies like tenofovir alafenamide based products - Genvoya, Odefsey, Descovy, Biktarvy and Truvada. The portfolio also includes hepatitis C virus drugs like Harvoni and Epclusa and HBV drug. The first cell therapy approved for the treatment of adult patients with relapsed or refractory large B-cell lymphoma, has diversified Gilead's portfolio. Tecartus, another CAR T-cell therapy, was granted an accelerated approval in the United States for the treatment of relapsed or refractory mantle cell lymphoma. The company is also working on diversifying and growing its business beyond antivirals into other therapeutic areas. Gilead is also making inroads in the oncology space with strategic collaborations and acquisitions.

Gilead Sciences, Inc. Statistics

Valuation Measures

Market Capitalization ²	83.52B
Enterprise Value	103.70B
Enterprise Value/EBITDA (ttm)	10.07
Price to Earnings Ratio (ttm)	9.96
Price to Book (mrq)	3.67
Price to Sales (ttm)	3.07
Price to Cash (ytd)	7.48

Profitability

Gross Margin (ttm)	76.13%
Operating Margin (ttm)	31.17%
Profit Margin (ttm)	20.69%
Return on Equity (ttm)	38.85%
Return on Invested Capital (ttm)	12.31%
Return on Assets (ttm)	13.60%

Income Statement

Revenue (ttm)	27.12B
Revenue Per Share (ttm)	21.77
Gross Profit (ttm)	20.62B
EBITDA (ttm)³	10.30B
Net Income Avi to Common (ttm)	5.67B
Diluted EPS (ttm)	4.50

Share Statistics

Beta (5Y Monthly)	0.19
52-Week Change	-18.54%
S&P500 52-Week Change	24.56%
S&P500 Member	Yes
Stock Optionable	Yes
Total Shares Outstanding ¹	1.25B
Dividend Yield	4.60%
Float ⁴	1.24B
% Held by Insiders	0.29%
% Held by Institutions	83.67%

Balance Sheet

Total Cash (mrq)	7.26B
Total Cash Per Share (mrq)	5.83
Total Debt (mrq)	26.27B
Total Debt/Equity (mrq)	115.46%
Current Ratio (mrq)	1.43%
Quick Ratio (mrq)	1.27%
Book Value Per Share (mrq)	18.26

Cash Flow

Operating Cash Flow Per Share (ytd)	6.36
Free Cash Flow (ytd)	7.42B

Table Key

mrq = Most Recent Quarter

ttm = Trailing Twelve Months

ytd = Year To Date

Footnotes

Data provided by Zacks Investment Research or calculated by FXEmpire. Stock price provided by Xignite. All numbers are rounded to the closest decimal.

¹ Total Shares outstanding is taken from the most recently filed quarterly or annual report.

² Market Cap is calculated using total shares outstanding and the most recent share price.

³ EBITDA is calculated using methodology that may differ from that used by a company in its reporting.

⁴ The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.

Gilead Sciences, Inc.

Trade With A Regulated Broker